NEW YORK, June 19, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Edwards Lifesciences Corp. (NYSE: EW), Hologic Inc. (NASDAQ: HOLX), Novartis AG (NYSE: NVS), CareFusion Corporation (NYSE: CFN) and DaVita HealthCare Partners, Inc. (NYSE: DVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3876-100free.
--
Edwards Lifesciences Corp. Analyst Notes
On June 16, 2014, Edwards Lifesciences Corp. (Edwards) announced that it has received the approval of the United States Food and Drug Administration (FDA) for its Edwards SAPIEN XT transcatheter aortic heart valve for the treatment of high-risk and inoperable patients suffering from severe symptomatic aortic stenosis. The Company informed that the Edwards SAPIEN XT valve, along with the NovaFlex+ transfemoral delivery system, and the Ascendra+ transapical and transaortic delivery systems, will be immediately available to patients at leading cardiovascular centers nationwide. Edwards Corporate Vice President for Transcatheter Heart Valves, Larry L. Wood, commented, "The SAPIEN family of valves has been used in the treatment of more than 70,000 patients globally - with the majority of those patients treated with SAPIEN XT - and we look forward to Heart Teams across America transforming the lives of even more patients with this advanced transcatheter valve." The full analystnotes on Edwards Lifesciences are available to download free of charge at:
http://www.analystsreview.com/Jun-19-2014/EW/report.pdf
--
Hologic Inc. Analyst Notes
On June 11, 2014, Hologic Inc. (Hologic) announced that two products from its 3D mammography platform have been chosen by Premier Inc. to be showcased at 2014 Breakthroughs Conference and Exhibition in San Antonio, Texas. Hologic's C-View software option (low-dose 3D mammography) and Affirm 3D-guided breast biopsy are two of the 16 medical innovations to be presented at the conference's sixth annual Innovation Celebration. "We are honored to have our low-dose 3D mammography and 3D-guided breast biopsy products recognized at Premier's Innovation Celebration event," said Peter J. Valenti III, Division President, Breast Health at Hologic. The Company's C-View software is designed to generate 2D images from 3D mammography image slices, eliminating the need for a separate 2D exposure during a Hologic 3D mammography exam. The full analyst notes on Hologic are available to download free of charge at:
http://www.analystsreview.com/Jun-19-2014/HOLX/report.pdf
--
Novartis AG Analyst Notes
On June 16, 2014, Novartis AG (Novartis) announced that the US Food and Drug Administration (FDA) licensed its manufacturing facility in Holly Springs, North Carolina for the production of cell-culture influenza vaccines, making the Company's facility the first to become US pandemic-ready site. Novartis uses cell-culture technology to produce Flucelvax® (Influenza Virus Vaccine), which was the first FDA-approved seasonal influenza vaccine not manufactured with chicken eggs. Novartis' Vaccines Division Head, Andrin Oswald commented, "Cell-culture technology is the first major advancement in influenza vaccine production in the US in more than 40 years. We are proud to be at the forefront of this innovation, which will allow us to deliver on our public health and health security commitments. With this award-winning, state-of-the-art facility, we will be able to not only offer US consumers an antibiotic- and preservative-free alternative for the yearly seasonal flu vaccination, but also be better prepared for future pandemic threats." With the licensure of the Holly Springs facility, Flucelvax will be produced in the US for the first time. The full analyst notes on Novartis are available to download free of charge at:
http://www.analystsreview.com/Jun-19-2014/NVS/report.pdf
--
CareFusion Corporation Analyst Notes
On June 16, 2014, CareFusion Corporation (CareFusion) announced the Canadian launch of the Alaris® System to help enhance IV medication safety. The Company informed that the new version of Guardrails® Suite MX safety software includes improved protection for infant and pediatric infusions where weight is a critical factor in drug and fluid dosages and protection. The new system also features device notification of non-Guardrails programming and can alert the clinician in the event of an unintentional closed clamp on a secondary infusion when used in conjunction with CareFusion secondary infusion sets. Infusion for CareFusion Senior Vice President and General Manager, J.C. Kyrillos commented, "Patient safety is at the core of this latest release, with enhanced protection against medication errors and improved workflow to increase safety software compliance. The new release provides additional therapy-specific dosing, enhanced messaging for clinicians and earlier notifications of certain alarm conditions, reaffirming our position as a market and clinical leader." The full analyst notes on CareFusion are available to download free of charge at:
http://www.analystsreview.com/Jun-19-2014/CFN/report.pdf
--
DaVita HealthCare Partners, Inc. Analyst Notes
On June 16, 2014, DaVita HealthCare Partners, Inc.'s (DaVita) stock slipped slightly by 0.02 points or 0.03% to close trading at $70.77. Over the past three months of trading, DaVita's stock gained 3.77% while the S&P 500 also marked an increase of 5.25% during the same period. The full analyst notes on DaVita are available to download free of charge at:
http://www.analystsreview.com/Jun-19-2014/DVA/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
